title: [Metabolic Syndrome as a marker of cardiovascular events in hypertensives in primary prevention].
abstract: OBJECTIVE
  The aim of this study was to assess the impact of metabolic syndrome (MS) as a predictor of cardiovascular events (CVE) in hypertensives in primary prevention.
  
  
  METHODS
  This retrospective study involved 2410 non-diabetic, hypertensive patients (52% women, 43% with MS), without previous CVE. The total follow-up was 13096 patient-years with a median of 4,5 years (IIQ; 2,2-7,3).
  
  
  RESULTS
  Patients with metabolic syndrome did not have more risk of CVE (HR 1,19; CI 95%:0,89-1,58; p=0,292), 183 patients had a CVE, 88 in patients with MS (15,4; CI 95%:12,4-19,0 patients-years), and 95 in patients without MS (13,0; CI 95%:10,5-15,9 patients/years) (p=0,279). In a multivariate analysis corrected for other factors, only age (HR 1,08; CI 95%: 1,07-1,10; p=0,001), male gender (HR 1,77; CI 95%: 1,27-2,45; p=0,001), smoking (HR 2,95; CI 95%: 2,01-4,34; p=0,001) at the beginning, and values of systolic arterial pressure ≥160 mm Hg (HR 1,83; CI 95%: 1,17-2,89; p=0,009) and cholesterol-low density lipoproteins ≥160 mg/dl (HR 1,58; CI 95%: 1,05-2,38; p=0,029) during the follow-up, were associated with new CVE.
  
  
  CONCLUSIONS
  In hypertensive non-diabetic patients in primary prevention the diagnosis of metabolic syndrome did not add any significant prediction about future CVE over the traditional risk factors. Systolic arterial pressure ≥160 mm Hg and cholesterol-low density lipoproteins ≥160 mg/dl, respectively, during the follow up were factors related to new CVE.
authors.affiliation: Unidad de Hipertensión y Riesgo Vascular, Medicina Interna, Hospital de Sagunto, Agencia Valenciana de Salud, Sagunto, España.
authors.forename: José Antonio
authors.initials: JA
authors.lastname: Costa
authors.forename: Enrique
authors.initials: E
authors.lastname: Rodilla
authors.forename: Joaquín
authors.initials: J
authors.lastname: Cardona
authors.forename: Carmen
authors.initials: C
authors.lastname: González
authors.forename: José María
authors.initials: JM
authors.lastname: Pascual
mesh_terms: D000328:Adult; D000368:Aged; D002561:Cerebrovascular Disorders / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000628:therapy; D015994:Incidence; D053208:Kaplan-Meier Estimate; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications*; D008875:Middle Aged; D015999:Multivariate Analysis; D017202:Myocardial Ischemia / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D058729:Peripheral Arterial Disease / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D011322:Primary Prevention; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors